J&J gets Priority Review designation for nipocalimab BLA

Johnson & Johnson (NYSE:JNJ) has received Priority Review designation from the FDA for the Biologics License Application for its drug nipocalimab in the treatment of antibody-positive patients with generalized myasthenia gravis.

Nipocalimab was also recently granted Breakthrough Therapy Designation by